TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9595177

Group type: EXPERIMENTAL
Intervention: TBF for hand warming
Number of subjects: 70

Group type: COMPARATOR
Intervention: TBF for hand cooling
Number of subjects: 70

Group type: COMPARATOR
Intervention: TBF for stabilization of hand temperature
Number of subjects: 70

Group type: COMPARATOR
Intervention: Biofeedback to suppress alpha in the EEG
Number of subjects: 70
Study: 8236405

Group type: EXPERIMENTAL
Intervention: ivermectin treatment
Number of subjects: 7148
Study: 3317349

Group type: EXPERIMENTAL
Intervention: 20 micrograms SmithKline Biologicals recombinant yeast-derived hepatitis B vaccine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 10 micrograms Merck Sharp & Dohme recombinant yeast-derived hepatitis B vaccine
Number of subjects: 90
Study: 31746760

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting Resolute stent (R-ZES) in CTO
Number of subjects: 5487

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting Resolute stent (R-ZES) in rec-TO
Number of subjects: 5487

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting Resolute stent (R-ZES) in non-TO
Number of subjects: 5487
Study: 29769165

Group type: EXPERIMENTAL
Intervention: Potassium ferrate haemostatic patch (PFHP)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control (no PFHP)
Number of subjects: 180
Study: 27524882

Group type: COMPARATOR
Intervention: Weekly paclitaxel (wPTX) 80 mg/m² intravenously on days 1, 8, and 15, every 4 weeks
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (wPTX) plus valproic acid (VPA) at 7.5 mg/kg twice daily
Number of subjects: 66

Group type: COMPARATOR
Intervention: Weekly paclitaxel (wPTX)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (wPTX) plus valproic acid (VPA)
Number of subjects: 66
Study: 24716775

Group type: EXPERIMENTAL
Intervention: Computer Assisted Telephone Interviews (CATI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-administered paper surveys
Number of subjects: 0
Study: 22670904

Group type: EXPERIMENTAL
Intervention: Vismodegib
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 20819425

Group type: EXPERIMENTAL
Intervention: Mini-subvastus approach
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard approach
Number of subjects: 68
Study: 18503367

Group type: EXPERIMENTAL
Intervention: Pick-up method
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Basin dissection
Number of subjects: 92
Study: 15668500

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamin supplementation (500 mg vitamin C and 400 IU vitamin E daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 14504165

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg plus droperidol 1.25 mg after induction and droperidol 1.25 mg 12 h later (Group 1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg plus dexamethasone 8 mg after induction and placebo 12 h later (Group 3)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Dexamethasone 8 mg plus droperidol 1.25 mg after induction and droperidol 1.25 mg 12 h later (Group 2)
Number of subjects: 90
Study: 10334518

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (semustine, vincristine, and fluorouracil (5-FU) - MOF regimen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (portal venous infusion of 5-FU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant 5-FU and leucovorin (LV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant 5-FU and LV compared with 5-FU and levamisole (LEV) and with the combination of 5-FU, LV, and LEV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy overall
Number of subjects: 0
Study: 10160470

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine mesylate (DHE)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sumatriptan
Number of subjects: 100
Study: 1743824

Group type: EXPERIMENTAL
Intervention: Vodka-tonic beverage containing a dose of vodka sufficient to induce a peak blood alcohol level of 0.05%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tonic water (control)
Number of subjects: 40
Study: 6459764

Group type: EXPERIMENTAL
Intervention: Piperacillin (2 g)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Penicillin G (4.8 X 10(6) U)
Number of subjects: 120
Study: 31412832

Group type: EXPERIMENTAL
Intervention: Work Stress Questionnaire (WSQ) intervention group
Number of subjects: 271

Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 271
Study: 27773349

Group type: EXPERIMENTAL
Intervention: Sexual Risk Event History Calendar (SREHC) assessment
Number of subjects: 181

Group type: COMPARATOR
Intervention: Guidelines for Adolescent Preventive Services (GAPS) assessment
Number of subjects: 181
Study: 25614446

Group type: EXPERIMENTAL
Intervention: First-line bevacizumab (15 mg/kg) plus carboplatin (AUC ×6) and paclitaxel (200 mg/m²) every 3 weeks (B + CP)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Second-line bevacizumab plus erlotinib (150 mg/d; B + E)
Number of subjects: 67
Study: 25012577

Group type: EXPERIMENTAL
Intervention: 150 mg clopidogrel MD with lansoprazole (30 mg/day)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 150 mg clopidogrel MD without lansoprazole
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 10 mg prasugrel MD with lansoprazole (30 mg/day)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 10 mg prasugrel MD without lansoprazole
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 82
Study: 22005941

Group type: EXPERIMENTAL
Intervention: Self-reported financial pressures
Number of subjects: 1361

Group type: EXPERIMENTAL
Intervention: Perceived financial burden
Number of subjects: 1361

Group type: EXPERIMENTAL
Intervention: Presence of financial barriers
Number of subjects: 1361

Group type: EXPERIMENTAL
Intervention: Being uninsured
Number of subjects: 1361

Group type: EXPERIMENTAL
Intervention: Non-adherence
Number of subjects: 1361
Study: 19542996

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 80

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 80
Study: 17578365

Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogen 0.625 mg/day (n = 35)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Intranasal 300 microg/day estradiol hemihydrate (n = 33)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Percutaneous gel 1.5 mg/day estradiol hemihydrate (n = 32)
Number of subjects: 132

Group type: COMPARATOR
Intervention: No treatment (control group, n = 32)
Number of subjects: 132
Study: 15056208

Group type: EXPERIMENTAL
Intervention: Adult's emotional displays during a 1‐hr delay
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Adult's emotional displays during a 3 min delay
Number of subjects: 2
Study: 15477366

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) 100 mg weekly intramuscularly plus levonorgestrel (LNG) 62.5 or 31.25 microg orally daily
Number of subjects: 7
Study: 10692718

Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 257

Group type: COMPARATOR
Intervention: Sumatriptan 25 mg
Number of subjects: 257
Study: 8591851

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of human albumin
Number of subjects: 294

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study: 1936480

Group type: EXPERIMENTAL
Intervention: Insulin therapy (short and intermediate‐acting insulin before breakfast and dinner)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combination of 21 mg of glibenclamide and 1.5 g of metformin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intensified insulin therapy (6 weeks of intermediate and short‐acting insulin 3 times daily)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sulfonylurea therapy (21 mg of glibenclamide/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intermittent insulin therapy
Number of subjects: 36
Study: 7286028

Group type: EXPERIMENTAL
Intervention: medigoxin
Number of subjects: 33

Group type: COMPARATOR
Intervention: digoxin
Number of subjects: 33
Study: 30455233

Group type: EXPERIMENTAL
Intervention: Mefloquine (two 15-mg/kg doses at least 1 month apart)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 264
Study: 29895329

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 2000
Study: 27225013

Group type: EXPERIMENTAL
Intervention: Micronised progesterone (Utrogestan(®), Besins Healthcare) at a dose of 400 mg (two vaginal capsules of 200 mg) administered twice daily from soon after a positive urinary pregnancy test until 12 completed weeks of gestation.
Number of subjects: 836

Group type: COMPARATOR
Intervention: Placebo vaginal capsules administered twice daily from soon after a positive urinary pregnancy test until 12 completed weeks of gestation.
Number of subjects: 836

Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 836

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 836

Group type: EXPERIMENTAL
Intervention: Economic analysis
Number of subjects: 836
Study: 24090620

Group type: EXPERIMENTAL
Intervention: Caffeinated beer (69mg caffeine/12oz glass)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Non-caffeinated beer
Number of subjects: 64
Study: 22871096

Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation (PS)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation + food supplementation (PS+FS)
Number of subjects: 507
Study: 20237041

Group type: EXPERIMENTAL
Intervention: Bowel preparation (n = 26)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Native group (no bowel preparation) (n = 39)
Number of subjects: 65
Study: 17345768

Group type: EXPERIMENTAL
Intervention: DD3 mRNA expression in prostate cancer tissues (PCa)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: DD3 mRNA expression in benign prostatic hyperplasia tissues (BPH)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: DD3 mRNA expression in normal prostate tissues (NP)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Diagnostic value of DD3 mRNA
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sensitivity of DD3 mRNA for diagnosing prostate cancer
Number of subjects: 102

Group type: COMPARATOR
Intervention: Specificity of DD3 mRNA for diagnosing prostate cancer
Number of subjects: 102

Group type: COMPARATOR
Intervention: Accuracy of DD3 mRNA for diagnosing prostate cancer
Number of subjects: 102

Group type: COMPARATOR
Intervention: Positive predictive value of DD3 mRNA for diagnosing prostate cancer
Number of subjects: 102

Group type: COMPARATOR
Intervention: Negative predictive value of DD3 mRNA for diagnosing prostate cancer
Number of subjects: 102

Group type: COMPARATOR
Intervention: Positive likelihood ratio of DD3 mRNA for diagnosing prostate cancer
Number of subjects: 102

Group type: COMPARATOR
Intervention: Negative likelihood ratio of DD3 mRNA for diagnosing prostate cancer
Number of subjects: 102
Study: 16252380

Group type: EXPERIMENTAL
Intervention: Nimodipine (n=50)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Fluoxetine-nimodipine (n=50)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Fluoxetine alone (control group, n=51)
Number of subjects: 101
Study: 12010353

Group type: EXPERIMENTAL
Intervention: Protease inhibitors (PIs)
Number of subjects: 1251
Study: 9443470

Group type: EXPERIMENTAL
Intervention: 5 mg/d donepezil
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: 10 mg/d donepezil
Number of subjects: 473

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 473
Study: 7872324

Group type: EXPERIMENTAL
Intervention: Low calcium dialysate (2.00 mEq/L; LCa)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard calcium dialysate (3.5 mEq/L; SCa)
Number of subjects: 103
Study: 30700485

Group type: EXPERIMENTAL
Intervention: Reversed total shoulder arthroplasty (RTSA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 0
Study: 30891991

Group type: EXPERIMENTAL
Intervention: Malaria elimination assessment in Suzhou City
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Malaria elimination review assessment in Wujiang District
Number of subjects: 0

Group type: COMPARATOR
Intervention: National assessment criteria for malaria elimination
Number of subjects: 0
Study: 25613322

Group type: EXPERIMENTAL
Intervention: Walking (brisk walking)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Balance training (balance and strength training)
Number of subjects: 90
Study: 24498872

Group type: EXPERIMENTAL
Intervention: Decitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment choice of supportive care or cytarabine
Number of subjects: 0
Study: 23284983

Group type: COMPARATOR
Intervention: Low-to-moderate alcohol drinkers (1 to 2 drinks/day)
Number of subjects: 3088

Group type: COMPARATOR
Intervention: Heavy drinkers (>3 drinks/day)
Number of subjects: 3088

Group type: EXPERIMENTAL
Intervention: Male drinkers consuming ≥ 90 g/d (≈8 drinks/d)
Number of subjects: 3088

Group type: EXPERIMENTAL
Intervention: Higher proportion of alcohol intake from beer
Number of subjects: 3088
Study: 19694743

Group type: EXPERIMENTAL
Intervention: Gefitinib after 5 days treatment with phenytoin (5 mg kg(‐1) daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control phase (gefinitib alone)
Number of subjects: 18
Study: 17375635

Group type: EXPERIMENTAL
Intervention: Intravenous sedation and topical pharyngeal anesthesia (midazolam 0.035 mg x kg(‐1) and continuous propofol infusion)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Topical pharyngeal anesthesia alone
Number of subjects: 170
Study: 15472672

Group type: EXPERIMENTAL
Intervention: Assessment of colonic pit patterns by experienced endoscopists using Kudo classification
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Prediction of histopathology based on pit pattern diagnosis
Number of subjects: 215
Study: 11584683

Group type: EXPERIMENTAL
Intervention: i.v.‐thrombolysis with rtPA
Number of subjects: 103
Study: 9785068

Group type: EXPERIMENTAL
Intervention: Intravenous tenoxicam (40 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rectal diclofenac (100 mg)
Number of subjects: 0
Study: 7511924

Group type: EXPERIMENTAL
Intervention: Lithium supplementation (400 micrograms/d of lithium orally in tablets composed of naturally lithium-rich brewer's yeast for 4 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (normal, lithium-free brewer's yeast)
Number of subjects: 24
Study: 17171950

Group type: EXPERIMENTAL
Intervention: Vecuronium with sufentanil (5 microg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pancuronium with sufentanil (5 microg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Beta-blockers (in groups B-P and B-V)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-beta-blockers (in groups NB-P and NB-V)
Number of subjects: 24
Study: 31923462

Group type: EXPERIMENTAL
Intervention: EtFOSAA
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: PFOS
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: EtFOSAA-to-PFOS ratio
Number of subjects: 397
Study: 29889693

Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide (PPS23) vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sequential administration of pneumococcal conjugate vaccine followed by PPS23 vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Annual influenza vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Influenza vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quadrivalent human papillomavirus vaccine
Number of subjects: 0
Study: 28588007

Group type: EXPERIMENTAL
Intervention: Education Against Tobacco (EAT) intervention - two medical student-led interactive modules totaling 120 minutes
Number of subjects: 1504

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1504

Group type: EXPERIMENTAL
Intervention: Education Against Tobacco (EAT) intervention
Number of subjects: 1504
Study: 26104826

Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 17

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 17
Study: 24073583

Group type: EXPERIMENTAL
Intervention: Recurrent SOM
Number of subjects: 67

Group type: COMPARATOR
Intervention: Non-recurrent SOM
Number of subjects: 67

Group type: COMPARATOR
Intervention: Simple adenoid hypertrophy
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Simple adenoid hypertrophy (age 3 to 6 subgroup)
Number of subjects: 67
Study: 21440829

Group type: EXPERIMENTAL
Intervention: Combigan®
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 19004038

Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 98

Group type: COMPARATOR
Intervention: Calcitriol + calcium
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Alendronate + calcium
Number of subjects: 98
Study: 15990257

Group type: EXPERIMENTAL
Intervention: CEE (0.625 mg/daily)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: CEE + MPA (0.625 mg/daily + 2.5 mg/daily)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: CEE + NA (0.625 mg/daily + 5 mg/daily)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg once daily)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 12829067

Group type: EXPERIMENTAL
Intervention: ONCAB (on-pump)
Number of subjects: 54

Group type: COMPARATOR
Intervention: OPCAB (off-pump)
Number of subjects: 54
Study: 10951278

Group type: EXPERIMENTAL
Intervention: Broad-spectrum sunscreens with SPF 10 (containing organic UV filters or TiO2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ex vivo UV exposure of human skin with a single dose of 200 mJ/cm2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed epidermal cell lymphocyte reaction
Number of subjects: 0
Study: 8899082

Group type: EXPERIMENTAL
Intervention: famotidine 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ranitidine 75 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 1801153

Group type: EXPERIMENTAL
Intervention: Amocarzine (3 mg/kg twice daily and postprandial for three consecutive days)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (no chemotherapy)
Number of subjects: 148
Study: 6409272

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg, 20 mg, and 30 mg three times daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 15
Study: 30898331

Group type: EXPERIMENTAL
Intervention: MBRP-A (intervention plus usual-care; N = 64)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control (usual-care-alone; N = 59)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: MBRP-A
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control
Number of subjects: 123
Study: 28714768

Group type: EXPERIMENTAL
Intervention: Oatmeal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cornflakes
Number of subjects: 24

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 24
Study: 23959544

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: S(‐)-amlodipine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (N w‐nitro‐L‐arginine, Ro 31‐8220)
Number of subjects: 24
Study: 22019083

Group type: EXPERIMENTAL
Intervention: Frontal αTMS
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Parietal αTMS
Number of subjects: 78

Group type: COMPARATOR
Intervention: Frontal sham
Number of subjects: 78

Group type: COMPARATOR
Intervention: Parietal sham
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: αTMS with concomitant typical neuroleptics
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: EEG normalization (Q factor increase)
Number of subjects: 78
Study: 20415370

Group type: EXPERIMENTAL
Intervention: Minimally invasive total knee arthroplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional total knee arthroplasty
Number of subjects: 0
Study: 18030197

Group type: EXPERIMENTAL
Intervention: High-spatial-resolution MR imaging at 3 Tesla
Number of subjects: 18
Study: 15013654

Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted behavioral therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxybutynin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy (both drug and behavioral therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11396779

Group type: EXPERIMENTAL
Intervention: 50 microg selenium as L-selenomethionine during pregnancy and 12 months postpartum
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo during pregnancy and 12 months postpartum
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 50 microg selenium as L-selenomethionine for non-pregnant women
Number of subjects: 52
Study: 9734726

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Number of subjects: 6
Study: 7753720

Group type: EXPERIMENTAL
Intervention: AIDS educational programs (specific types not detailed)
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Pre-test counseling
Number of subjects: 497
Study: 2661231

Group type: EXPERIMENTAL
Intervention: Ceftriaxone single dose plus metronidazole
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ceftazidime multiple doses plus metronidazole
Number of subjects: 60
Study: 130835

Group type: EXPERIMENTAL
Intervention: Selenium sulfide shampoo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topically applied amphotericin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Suppression of scalp microorganisms
Number of subjects: 0
Study: 30545967

Group type: EXPERIMENTAL
Intervention: Parachute
Number of subjects: 23

Group type: COMPARATOR
Intervention: Empty backpack (control)
Number of subjects: 23
Study: 28459238

Group type: EXPERIMENTAL
Intervention: Kidney reinforcing and Qi tonifying (KQ)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Kidney reinforcing and blood circulation invigorating (KC)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: All treated groups
Number of subjects: 111
Study: 25606338

Group type: EXPERIMENTAL
Intervention: Bioptron light therapy (8 sessions, 3 times a week)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Wrist splinting
Number of subjects: 44
Study: 22822024

Group type: EXPERIMENTAL
Intervention: IFN‐γ (100 μg/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GM‐CSF (4 μg/kg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 18